Boehringer Ingelheim licenses Immunitas antibody program

Boehringer Ingelheim and Immunitas Therapeutics announced a global licensing agreement for a preclinical antibody program targeting chronic inflammatory and autoimmune diseases. Under the terms, Boehringer Ingelheim gains worldwide rights to develop, manufacture, and commercialize the program. Immunitas Therapeutics will receive an upfront payment and is eligible for up to €407.5 million in development, regulatory, and commercial milestone payments, along with tiered royalties on future sales. This collaboration aims to address unmet medical needs by developing therapies that selectively target pathogenic cells, offering the potential for deeper and more durable disease control than current treatments. The agreement strengthens Boehringer Ingelheim's immunology pipeline and provides Immunitas Therapeutics with resources to advance its therapeutic into clinical development.